Chronic hepatitis B virus (HBV) infection continues to be a crucial health issue worldwide as more than 200 million individuals are positive for hepatitis B surface antigen (HBsAg) [1]. Patients with chronic HBV infection are at an increased risk of developing liver cirrhosis and hepatocellular carcinoma (HCC), resulting in over one million deaths per year [2]. So far, there is no cure for HBV and prolonged suppression of viral replication via inhibiting reverse transcriptase by nucleos(t)ide analogue (NA) treatment is the only way to minimize their liver-related complications and to reduce HCC risk [2].
Three potent NAs, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide, and entecavir, are recommended as first-line treatment by clinical practice guidelines. Besifovir dipivoxil maleate (BSV) is a new acyclic nucleotide phosphonate with potent antiviral activity against HBV [3,4]. In this study, Song et al. [5] explored BSV’s antiviral efficacy and drug safety up to 192 weeks in two groups: 170 patients continuing BSV treatment (BSV-BSV) and 152 patients switching from TDF to BSV after 48 weeks (TDF-BSV). They found more than 90% of virological response rates over 192 weeks in both groups and no drug-resistant mutations to BSV. Bone mineral density and renal function were well preserved in the BSV-BSV group, whereas these initially worsened then recovered after switching therapy in the TDF-BSV group. However, only one participant achieved HBsAg loss in both groups [5].
Prolonged NA treatment to suppress viral replication is the mainstay treatment strategy in current practice. According to this study, 4-year viral suppression is still far from achieving HBsAg clearance [5], which is also compatible with other clinical studies using different NA treatments [6,7]. In addition to the on-going clinical trials aiming at HBsAg clearance [8], there are several issues that need to be addressed. First, as the goal for prolonged NA treatment is to reduce HCC risk, a precise HCC prediction model in addition to serum HBV DNA and alanine aminotransferase levels is mandatory to decide who should receive early antiviral treatment [9]. For example, around 50% of HBeAg-negative patient without liver cirrhosis are in grey zone for antiviral treatment and their prognosis is heterogenous [10-12]. With a better prediction model integrated with more viral markers [13,14], we may be able to identify some of the grey-zone patients who need early antiviral treatment due to the elevated HCC risk.
The second issue is how to predict the residual HCC risk after prolonged antiviral treatment to minimize viral replication. In addition to host factors, including age and sex [15], surrogate markers for liver fibrosis have shown their potential to improve the prediction performance of current HCC prediction models [16,17]. A better HCC prediction model may impact how to perform cost-effective surveillance for HCC.
In summary, although BSV provides us another NA choice to suppress viral replication activity, it is still far from achieving HBsAg clearance. The current unmet need for physicians is to identify the patients with high HCC risk for an early antiviral treatment and to define the residual HCC risk after long-term antiviral treatment, which may impact the HCC surveillance system.
Abbreviations
- BSV
besifovir dipivoxil maleate
- HBsAg
hepatitis B surface antigen
- HBV
hepatitis B virus
- HCC
hepatocellular carcinoma
- NA
nucleos(t)ide analogue
- TDF
tenofovir disoproxil fumarate
Footnotes
Conflicts of Interest
T-C. T. has served on speaker’s bureaus for Bristol-Myers Squibb and Gilead Sciences and received research grant from Gilead Sciences.
REFERENCES
- 1.Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–1555. doi: 10.1016/S0140-6736(15)61412-X. [DOI] [PubMed] [Google Scholar]
- 2.Tseng TC, Kao JH. Elimination of hepatitis b: is it a mission possible? BMC Med. 2017;15:53. doi: 10.1186/s12916-017-0820-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Yim HJ, Kim W, Ahn SH, Yang JM, Jang JY, Kweon YO, et al. Besifovir dipivoxil maleate 144-week treatment of chronic hepatitis B: an open-label extensional study of a phase 3 trial. Am J Gastroenterol. 2020;115:1217–1225. doi: 10.14309/ajg.0000000000000605. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Ahn SH, Kim W, Jung YK, Yang JM, Jang JY, Kweon YO, et al. Efficacy and safety of besifovir dipivoxil maleate compared with tenofovir disoproxil fumarate in treatment of chronic hepatitis B virus infection. Clin Gastroenterol Hepatol. 2019;17:1850–1859.e4. doi: 10.1016/j.cgh.2018.11.001. [DOI] [PubMed] [Google Scholar]
- 5.Song DS, Kim W, Ahn SH, Yim HJ, Jang JY, Kweon YO, et al. Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: results of 192-week phase 3 trial. Clin Mol Hepatol. 2021;27:346–359. doi: 10.3350/cmh.2020.0307. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196–206. doi: 10.1016/S2468-1253(16)30107-8. [DOI] [PubMed] [Google Scholar]
- 7.Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475. doi: 10.1016/S0140-6736(12)61425-1. [DOI] [PubMed] [Google Scholar]
- 8.Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4:545–558. doi: 10.1016/S2468-1253(19)30119-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol. 2020;26:261–279. doi: 10.3350/cmh.2020.0032. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Di Bisceglie AM, Lombardero M, Teckman J, Roberts L, Janssen HL, Belle SH, et al. Determination of hepatitis B phenotype using biochemical and serological markers. J Viral Hepat. 2017;24:320–329. doi: 10.1111/jvh.12643. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Bonacci M, Lens S, Mariño Z, Londoño MC, Rodríguez-Tajes S, Mas A, et al. Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the grey zone. Aliment Pharmacol Ther. 2018;47:1397–1408. doi: 10.1111/apt.14613. [DOI] [PubMed] [Google Scholar]
- 12.Lee HW, Kim SU, Baatarkhuu O, Park JY, Kim DY, Ahn SH, et al. Progression of untreated minimally active chronic HBV infection compared to inactive infection. Clin Gastroenterol Hepatol. 2019;17:2808–2810. doi: 10.1016/j.cgh.2019.01.002. e2. [DOI] [PubMed] [Google Scholar]
- 13.Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140–1149.e3. doi: 10.1053/j.gastro.2012.02.007. quiz e13-e14. [DOI] [PubMed] [Google Scholar]
- 14.Tseng TC, Liu CJ, Hsu CY, Hong CM, Su TH, Yang WT, et al. High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology. 2019;157:1518–1529.e3. doi: 10.1053/j.gastro.2019.08.028. [DOI] [PubMed] [Google Scholar]
- 15.Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64:800–806. doi: 10.1016/j.jhep.2015.11.035. [DOI] [PubMed] [Google Scholar]
- 16.Tseng TC, Peng CY, Hsu YC, Su TH, Wang CC, Liu CJ, et al. Baseline Mac-2 binding protein glycosylation isomer level stratifies risks of hepatocellular carcinoma in chronic hepatitis B patients with oral antiviral therapy. Liver Cancer. 2020;9:207–220. doi: 10.1159/000504650. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Tseng TC, Choi J, Nguyen MH, Peng CY, Siakavellas S, Papatheodoridis G, et al. One-year fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. Hepatol Int. 2021;15:105–113. doi: 10.1007/s12072-020-10124-z. [DOI] [PMC free article] [PubMed] [Google Scholar]